ProQR Therapeutics (NASDAQ:PRQR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.
This is a breakdown of recent ratings and recommmendations for ProQR Therapeutics and Altimmune, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Risk & Volatility
ProQR Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Valuation & Earnings
This table compares ProQR Therapeutics and Altimmune’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ProQR Therapeutics||N/A||N/A||-$63.56 million||($1.55)||-3.99|
|Altimmune||$5.80 million||88.20||-$20.52 million||($0.98)||-14.05|
Altimmune has higher revenue and earnings than ProQR Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
55.9% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Altimmune shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares ProQR Therapeutics and Altimmune’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Altimmune beats ProQR Therapeutics on 8 of the 11 factors compared between the two stocks.
ProQR Therapeutics Company Profile
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.
Altimmune Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.